N/A N=566 A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events — 262; 65 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=319 An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain
Pain
Primary: Number of Participants With Insufficient Pain Relief After the Start of Double-Blind Period — 20; 43 number of participants — p=0.0001
Phase 4 N=66 Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest
Dissection of Thoracic Aorta
Primary: Incidence of Acute Kidney Injury Based on RIFLE Criteria
Phase 4 N=322 Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
Overactive Bladder
Primary: Percentage of Patients Continent (PPC) — 34.6; 17.1 Percentage of participants
Phase 2 N=70 A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients
Kidney Transplantation
Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus — 215.1; 206.6; 200.7; 197.6 ng*hr/mL
Phase 1 N=20 Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Breast Cancer
Primary: Maximum Tolerated Dose (MTD) — 10 milligrams
Phase 3 N=610 Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks — -4.5; -6.0 units on a scale — p=<0.001
Phase 2 N=41 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Myelofibrosis
Primary: Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16 — 78.0 Percentage of participants
Phase 2 N=183 An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
Pneumonia · Bacterial Pneumonia · Ventilator-Associated Pneumonia
Primary: Clinical Response Rates and 95% Confidence Intervals at the Test-of-Cure Assessment. — 63.9; 66.0; 64.4; 50.0 Percentage of participants
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
Phase 2 N=40 Effect of Milnacipran in Chronic Neuropathic Low Back Pain
Low Back Pain
Primary: Effect Size of VAS Pain — 24.8; 31.3 units on a scale
N/A N=175 French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Essential Thrombocythemia
Primary: Percentage of Subjects With Continuation of Anagrelide Hydrochloride at 6 Months: Withdrawal of Previous Cytoreductive Therapy Before Anagrelide Hydrochloride Initiation…
Phase 2 N=133 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..
Nerve Pain
Primary: Change From Baseline to Days 24-28 in Numerical Rating Scale (NRS) Average Pain Score. — -1.53; -1.54; -1.44 Scores on a scale
Phase 2 N=96 Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
Renal Impairment
Primary: Change From Baseline to Month 12 in Serum Creatinine — 2.52; 2.10; 2.22; 0.19 mg/dL — p=0.459
Phase 3 N=53 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
Essential Thrombocythemia (ET)
Primary: Percentage of Subjects Who Responded in Platelet Count — 67.9 percentage of subjects